OncoMatch/Clinical Trials/NCT06582017
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Is NCT06582017 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies QXL138AM for ovarian cancer.
Treatment: QXL138AM — Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical starting dose. Dose escalation in solid tumors (Part A1) will be followed by dose finding in multiple myeloma (Part A2). Part B consists of dose expansion in solid tumors (Part B1) and multiple myeloma (Part B2) using the recommended dose for expansion from Part A
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Pancreatic Cancer
Urothelial Carcinoma
Renal Cell Carcinoma
Hepatocellular Carcinoma
Colorectal Cancer
Gastric Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Non-Small Cell Lung Carcinoma
Prostate Cancer
Breast Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
prior exposure to a proteosome inhibitor
Must have received: IMiD
prior exposure to an IMiD
Must have received: anti-CD38-directed therapy
prior exposure to an anti-CD38-directed therapy
Cannot have received: anticancer therapy
Received prior anticancer therapy within 28 days or 5x the half-life (whichever is shorter) prior to the first dose of investigational product
Cannot have received: wide-field radiation therapy
Participants who received wide-field radiation therapy within 4 weeks prior to first dose of investigational product
Cannot have received: limited field radiation therapy
2 weeks for limited field radiation therapy
Cannot have received: major surgery
Major surgery within 30 days before first dose of investigational product
Lab requirements
Blood counts
Adequate organ function and bone marrow reserve
Kidney function
Adequate organ function and bone marrow reserve
Liver function
Adequate organ function and bone marrow reserve
Cardiac function
Adequate cardiac function as estimated by left ventricular ejection fraction
Adequate organ function and bone marrow reserve; Adequate cardiac function as estimated by left ventricular ejection fraction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Southern California · Los Angeles, California
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer · Los Angeles, California
- Hoag Memorial Hospital Presbyterian · Newport, California
- Sarah Cannon Research Institute - Denver DDU · Denver, Colorado
- Emory University - Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify